LivingWithPain.org CBD Trial explores whether cannabidiol can offer measurable relief for ongoing discomfort. This overview outlines what participants can expect from the current study and how the data may shape future pain care.
Researchers designed the initiative to address real-world pain patterns while maintaining rigorous safety standards. Early signals suggest that CBD may influence perception of intensity and support daily function for some individuals.
| Trial ID | Phase | Primary Focus | Participant Count |
|---|---|---|---|
| LW2024-CBD-01 | Phase II | Moderate to severe chronic pain | 180 |
| LW2024-CBD-02 | Phase III | Quality of life and sleep impact | 400 |
| LW2024-CBD-03 | Open-label extension | Long-term safety | Variable |
| LW2024-CBD-04 | Phase IIb | Dose optimization | 250 |
Study Design and Eligibility Criteria
Enrollment Process
Volunteers complete an online screener and then attend an in-person visit to confirm eligibility. Key factors include pain duration, current medications, and prior CBD use.
Randomization and Blinding
Participants are randomly assigned to receive either standardized CBD oil or a matched placebo. Study staff, participants, and outcome assessors remain blinded to group assignment.
Dosing Protocols and Safety Monitoring
Titration Phases
The trial uses a ramp-up schedule that starts at a low dose and increases gradually based on tolerance. Blood tests help detect any changes in liver enzymes or interactions with other drugs.
Adverse Event Tracking
Coordinated by an independent data safety board, ongoing monitoring captures side effects such as drowsiness, digestive changes, or mood shifts. Participants can withdraw at any time without losing medical care.
Measuring Pain Relief and Functional Outcomes
Primary and Secondary Endpoints
Researchers record average pain intensity on validated scales at baseline, four weeks, and twelve weeks. Secondary measures include sleep quality, mobility, and reduction in rescue medication use.
Patient-Reported Experiences
Daily digital diaries allow participants to note fluctuations in stiffness, mood, and overall comfort. These entries help researchers identify patterns that clinic visits might miss.
Legal, Ethical, and Regulatory Context
Compliance with Standards
The trial aligns with Good Clinical Practice guidelines and complies with local regulations regarding cannabis-derived compounds. Institutional review boards oversee participant consent processes.
Data Transparency
De-identified datasets are planned for future publication to support independent analysis. This approach encourages replication and strengthens public trust in the results.
Participation Pathway and Practical Guidance
- Complete the online eligibility screener and schedule an intake visit.
- Review consent documents and verify insurance or cost coverage details.
- Attend randomization and begin the assigned dosing schedule.
- Use the provided digital tools to log symptoms, medication use, and side effects.
- Attend scheduled follow-ups and communicate openly with study coordinators.
FAQ
Reader questions
How long does each study visit typically last?
In-clinic sessions usually last 60 to 90 minutes, including check-in, assessments, and discussion with the research team.
Can I continue using CBD after the trial ends?
Participants who complete the study may be offered an open-label extension or guidance on safe transition to ongoing use if appropriate.
Will I know whether I received CBD or placebo during the trial?
Blinding is preserved until the study concludes; unblinding occurs only for safety reasons or at the final analysis stage.
What should I do if I experience side effects while enrolled?
Contact the study hotline immediately so the medical team can evaluate the issue and decide whether dose adjustment or discontinuation is needed.